In this study, oral testosterone administered three times daily normalized serum testosterone levels in men with experimentally induced hypogonadism over nine days and significantly reduced SHBG.
7 citations
,
May 2012 in “International Journal of Andrology” This study found that an oral testosterone formulation normalized serum testosterone levels and significantly reduced SHBG in men with experimentally induced hypogonadism after nine days of treatment, suggesting potential efficacy for testosterone deficiency.
6 citations
,
November 2010 in “International Journal of Andrology” In a clinical trial, this study found that a modified slow-release oral testosterone formulation improved pharmacokinetics, delaying serum testosterone peaks and reducing serum DHT compared to immediate-release formulations, especially when combined with finasteride.
6 citations
,
February 2016 in “Journal of Microencapsulation” This study found that injectable finasteride microspheres provided a sustained drug release with a minimal initial burst in albino rabbits compared to oral suspension.
989 citations
,
August 2007 in “The Lancet” This article reviews the clinical features, diagnostic criteria, and possible genetic and environmental influences of polycystic ovary syndrome but provides no new research findings.